Newcelx Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Newcelx Ltd. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Newcelx Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 158.8% while net income fell 15.3%: a 143pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Newcelx Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 29.9% in a year.
Price chart
- 1 day-2.4%
- 1 week-2.4%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-2.16
Growth
- Share count change
- +29.9%
Cash
- Free cash flow (TTM)
- -$2.8M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for NCEL from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Newcelx Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$16 ~$13–$36 | Left out: out of range vs price (6.43x) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Newcelx Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.18 | — | — | — |
| Next | −$0.60 | +49% | — | 0% |
Positioning
- Short interest
- — of tradable shares
- Days to cover
- 1.84 at average volume
- Short interest, 1 month
- −35% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 65.6% of shares
- Employees
- 9 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $3m of assets due within a year against $4m of liabilities due within a year.
- Short-term assets cover long-term liabilities $3m short-term assets against $0 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +29.9%
- year over year
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Revel Michel CSO and Director | April 27, 2026 | Buy | 54,545 | $2.75 | $149,999 |
| Samuel Olivier Director | April 27, 2026 | Buy | 81,818 | $2.75 | $225,000 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Newcelx Ltd. in brief
- What does Newcelx Ltd. do?
- Newcelx Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Newcelx Ltd.'s stock ticker?
- Newcelx Ltd. trades under the ticker NCEL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Are insiders buying or selling Newcelx Ltd. stock?
- Over the last 12 months, Newcelx Ltd.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on Newcelx Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.